- Medically Reviewed by: Mr Mfazo Hove, Consultant Ophthalmic Surgeon
- Author: Mr Mfazo Hove
- Published: March 14, 2025
- Last Updated: August 18, 2026
TL;DR: The Best Place for ICL Surgery Is the One Still Looking After You in Year Twenty
Awards and technology are pleasant, but they are day-one arguments, and an Implantable Collamer Lens (ICL) is not a day-one operation. The lens will sit inside your eye for decades, it needs vault and endothelial monitoring across those decades, ¹ ⁴ and if your natural lens develops a cataract in later life, the ICL is removed as part of the transition to lens surgery. So the best place to get ICL surgery in London is the place whose clinical system is built for that entire arc. This page defines what “place” actually means for this operation, stage by stage, and ends with the test that separates providers: the Year-20 Test.
Here is the fact that should shape your entire choice of provider: an ICL is not an event. It is a decades-long relationship. The lens sits inside your eye, in front of your natural lens, and it needs to be respected for as long as it is there: the vault, the space between ICL and natural lens, should be checked, and your corneal endothelial cell count monitored over the years. ¹ And if, in later life, your natural lens develops a cataract, the ICL is removed as part of the transition to cataract surgery and an intraocular lens. Providers differ substantially in what happens after routine postoperative follow-up: ask specifically what monitoring is offered after year one, how long it continues and whether it is included in the original fee. The Blue Fin Vision® pathway is designed for the entire life of the lens.
What Makes an ICL Clinic Different From an ICL Surgeon?
The surgeon is an important individual variable, and the surgeon question has its own dedicated answer in Who Is the Best ICL Surgeon in London? But a surgeon operates inside a system, and the system is what you are actually buying when you choose a place: the diagnostics that produce the sizing, the theatre and its standards, the people who see you at every review, the record system that holds your baselines for decades, the written policies that say who pays for what, and the surgical infrastructure that exists for the rare patient whose lens needs repositioning, exchange or removal. ICL-specific research also quantifies the importance of the surrounding diagnostic system: a retrospective study of 2,772 eyes found that ICL size, sulcus-to-sulcus distance, central anterior chamber depth and implantation orientation substantially influenced postoperative vault prediction. ⁵ This page is the system half.
What Should an Excellent ICL Assessment Include?
Judge the place first by the depth of its assessment, because everything downstream depends on it. An excellent ICL assessment establishes refractive stability; measures the internal anatomy the lens will occupy, because sizing and the resulting postoperative vault are among the most important technical considerations in the entire procedure; records a baseline endothelial cell count, since the endothelium has very limited regenerative capacity in vivo and every future measurement will be interpreted against that number; examines the natural lens, the retina and the ocular surface; and tests the recommendation against the alternatives, laser and lens replacement, with a credible route to advising no surgery at all. If the place cannot describe its assessment in that kind of detail, it has described its priorities.
What Happens on the Day of Surgery?
ICL surgery is a relatively brief day-case procedure under anaesthetic drops: the folded lens is introduced through a small corneal opening, unfolds, and is positioned behind the iris in front of your natural lens. The place-level questions are about everything around those minutes: is the surgery performed by the consultant who assessed you; what are the theatre’s standards and governance; and is the predicted vault from your sizing checked against the measured vault at your early reviews, with intraocular pressure and recovery confirmed alongside it?
What Should the Provider Still Be Doing Five Years Later?
This is where places genuinely separate, because five years later the marketing has long stopped and only the system remains. The answer should be structured monitoring at defined intervals: vault, because long-term follow-up shows it can change gradually over the years; endothelial cell density against your recorded baseline, with ten-year data showing losses of approximately 3.8% to 4.5% in low- and normal-vault eyes; ⁴ pressure; and the state of your natural lens. At Blue Fin Vision® that structure is the Lifetime Monitoring Protocol™. A place with no answer beyond the final postoperative review has answered the five-year question by omission.
What If Something Goes Wrong?
Most ICL surgery is uneventful, and published evidence supports the effectiveness and safety of modern central-port ICL designs. ² The contemporary exchange evidence is also reassuring: in a recent high-volume series of 961 EVO ICL eyes, the size-related exchange or explant rate was 1.1%, with toric rotation accounting for six exchanges and five eyes exchanged because of initial vault concerns. ³ But different problems have different solutions, and a serious place can name them before you ask: a symptomatic residual or later refractive error may, where clinically appropriate, be managed with corneal refractive enhancement or, in selected circumstances depending on the cause, ICL repositioning, exchange or another refractive strategy; a vault outside the comfortable range may be observed or occasionally addressed; surface symptoms are treated as surface disease; a pressure rise has defined management; and a changing natural lens is managed as a lens problem, up to and including the transition to lens surgery. The place-level test is infrastructure: are those pathways performed within the provider’s own surgical system, or by onward referral?
What Does the Price Actually Include?
Provider policies vary: enhancement may be included for a defined period, subject to eligibility, charged separately or handled under provider-specific terms. Ask to see the written policy before surgery, and ask the same of monitoring, exchange and the eventual cataract pathway. A headline price whose relationship ends at the final review is not the same product as a pathway specified for decades. Ours is published before you pay:
Who Monitors My Vault and Endothelial Cells Over the Years?
- Approaches you may encounter elsewhere: Follow-up may end at the final post-operative review; ask what is offered beyond it.
- Blue Fin Vision®: The Lifetime Monitoring Protocol™ provides structured lifelong vault and endothelial monitoring at defined intervals within one system.
What If My Result Needs Fine-Tuning?
- Approaches you may encounter elsewhere: Provider policies vary: enhancement may be included for a defined period, charged separately or handled under provider-specific terms; ask to see the written policy before surgery.
- Blue Fin Vision®: Enhancement for eligible self-pay ICL patients is fully covered within 24 months, with no cost-sharing, in writing before surgery.
If I Develop a Cataract in Later Life, What Happens?
- Approaches you may encounter elsewhere: This is often outside the original provider’s scope entirely; ask who removes the ICL and what it costs.
- Blue Fin Vision®: A written position on the ICL-to-cataract transition, planned within the same clinical system that implanted the lens.
Who Removes or Exchanges the ICL If Ever Needed?
- Approaches you may encounter elsewhere: This may involve onward referral; ask.
- Blue Fin Vision®: Removal and exchange capability within Blue Fin Vision®’s own surgical pathway.
What Would Make Me Change ICL Provider?
Turn the question around. Suppose you had already chosen a clinic; what discoveries should make you walk away? I can list them, because they are the negatives of everything this operation requires. The surgeon who assessed you will not personally operate. No baseline endothelial cell count was taken, so year-ten monitoring has nothing to compare against. There is no defined vault follow-up beyond the early reviews. The provider cannot remove or exchange an ICL within its own pathway. The relationship formally ends at the final postoperative check, with nothing offered after year one. The enhancement terms cannot be shown to you in writing before you pay. And nobody can tell you what happens if you develop a cataract in thirty years. Any one of these is a weakness. Two or more is an answer.
The Year-20 Test
So here are ten questions framed entirely around the long term. Put them to every London provider on your shortlist, including us.
- Will the surgeon who assesses me personally perform my surgery, and will my later monitoring remain within the same governed clinical system with access to my original measurements?
- What is my baseline endothelial cell count, and where is it recorded?
- What vault do you predict for my eye, and when will the measured vault be checked against it?
- What structured monitoring exists after year one, at what intervals, and is it included in the fee?
- Who monitors my vault and endothelium in year ten, and what would trigger action?
- If my result needs fine-tuning, what are the written enhancement terms, and who pays?
- If my ICL ever needs repositioning, exchange or removal, is that performed within your own surgical pathway?
- If I develop a cataract in later life, who manages the transition, and is that plan written down today?
- If I move away, how do my baseline and follow-up data travel with me?
- Can I read all of the above before I pay anything?
A provider that cannot answer the year-twenty questions in writing has answered them anyway.
How Blue Fin Vision® Answers the Same Test
Consultant continuity from assessment through aftercare, within one governed clinical system holding your original measurements; a recorded endothelial baseline and predicted-versus-measured vault for every eye; structured lifelong vault and endothelial monitoring at defined intervals under the Lifetime Monitoring Protocol™; enhancement for eligible self-pay ICL patients fully covered within 24 months, in writing, with no cost-sharing; repositioning, exchange and removal within our own surgical pathway; a written ICL-to-cataract transition inside the Blue Fin Vision® Advantage; and records built to travel.
The system behind all of this is published: the Blue Fin Vision® Advantage, the Enhancement Policy, the ICL Surgery Checklist to test any provider against, including us, and transparent pricing on the ICL costs page.
So, What Is the Best Place to Get ICL Surgery in London?
The place designed for the whole life of the lens, and willing to prove it in writing before you pay. For how the London geography itself should and should not influence you, see Looking for the Best Place to Get ICL Surgery in London?, and book a consultation when you are ready to discuss your eyes with a consultant-led UK clinic offering documented outcomes and long-term ICL care.
References
- Packer M. The Implantable Collamer Lens with a central port design: review of the literature. Clin Ophthalmol. 2018;12:2427-2438. PMID: 30568421.
- Packer M. Meta-analysis and review: effectiveness, safety, and central port design of the intraocular collamer lens. Clin Ophthalmol. 2016;10:1059-1077. PMID: 27354760.
- Hirabayashi M, Virdi G, Nasser T, Libfraind L, Zapata EA, Abramson AJ, Parkhurst G. ICL exchanges or explants due to sizing in a United States high volume center. Clin Ophthalmol. 2025;19:2609-2614. doi:10.2147/OPTH.S528280. PMID: 40800717.
- Alfonso-Bartolozzi B, Fernández-Vega-Cueto L, Lisa C, Palacios A, Madrid-Costa D, Alfonso JF. Ten-year follow-up of posterior chamber phakic intraocular lens with central port design in patients with low and normal vault. J Cataract Refract Surg. 2024;50(5):441-447. doi:10.1097/j.jcrs.0000000000001379. PMID: 38085219.
- Yang Y, Long Z, Lei B, Liu W, Ye J. Clinical decision support system based on deep learning for evaluating implantable collamer lens size and vault after implantable collamer lens surgery: a retrospective study. BMJ Open. 2024;14(2):e081050. doi:10.1136/bmjopen-2023-081050. PMID: 38365302.
ABOUT THE AUTHOR
Mr Mfazo Hove
Consultant Ophthalmic Surgeon
MBChB MD FRCOphth CertLRS
Mr Mfazo Hove is a Consultant Ophthalmic Surgeon with experience spanning more than 57,000 procedures. He completed 6.5 years of specialist training at Moorfields Eye Hospital and served for five years as a consultant at the Western Eye Hospital, Imperial College Healthcare NHS Trust. He is the founder of Blue Fin Vision®, a consultant-led private ophthalmology practice operating across London, Essex, and Hertfordshire. His clinical expertise encompasses advanced cataract surgery, refractive lens replacement, laser vision correction, and implantable Collamer lenses (ICL).
A ZEISS Key Opinion Leader, Mr Hove is a respected international speaker with five invited engagements across seven cities in 2026:
- ZEISS China tour (Changsha, Shanghai, and Hangzhou, April – ZEISS APAC User Meeting)
- RCOphth Annual Congress – May – Manchester
- ZEISS EMEA User Meeting (Istanbul)
- ZEISS Lausanne User Meeting (Lausanne)
- European Society of Cataract and Refractive Surgeons Annual Congress (ESCRS, London)
